Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

To see complete record on, please visit this link

Id: NCT05019885

Organisation Name: Icahn School of Medicine at Mount Sinai

Overal Status: Recruiting

Start Date: August 26, 2022

Last Update: August 29, 2022

Lead Sponsor: Madeline Fields

Brief Summary: Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting. This study would like to examine the effectiveness of subanesthetic ketamine in outpatients who suffer from drug resistant epilepsy.

  • Drug Resistant Epilepsy
  • Medically Refractory Epilepsy
  • Refractory Epilepsy

Total execution time in seconds: 0.29737782478333